The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Tvardi Therapeutics
Consulting or Advisory Role - Tvardi Therapeutics
Research Funding - Tvardi Therapeutics
Patents, Royalties, Other Intellectual Property - Baylor College of Medicine; Tvardi Therapeutics
A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - Array BioPharma; Eisai; Exelixis; Genentech/Roche; QED Therapeutics; Signatera
Speakers' Bureau - Amgen; Deciphera; Eisai; Exelixis; Genentech/Roche; ipsen; Natera; SERVIER; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Marina Baretti
Consulting or Advisory Role - Exelixis; Incyte
 
Sunyoung S. Lee
No Relationships to Disclose
 
Aiwu Ruth He
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Genentech/Roche
Speakers' Bureau - AstraZeneca; bms; Eisai
Research Funding - AstraZeneca; Genentech; Merck
 
Richard D. Kim
Consulting or Advisory Role - Abbvie; AstraZeneca; Exelixis; Pfizer; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - AstraZeneca; Incyte
 
Bruce Shih-Li Lin
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Exelixis; Pfizer; QED Therapeutics; Seattle Genetics/Astellas
Research Funding - BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); FUJIFILM Toyama Chemistry (Inst); Incyte (Inst); Merck (Inst); Nucana (Inst); Relay Therapeutics (Inst); Tvardi Therapeutics (Inst); Zymeworks (Inst)
 
Thomas Enzler
Research Funding - Abbvie; Amgen; AstraZeneca; AstraZeneca; BioMed Valley Discoveries (Inst); CanBas; Exelixis; Exelixis; Five Prime Therapeutics; Hoosier Cancer Research Network; NeoImmuneTech; Taiho Oncology
 
Mohammed Najeeb Al Hallak
Speakers' Bureau - AstraZeneca; Guardant Health; Ipsen
(OPTIONAL) Uncompensated Relationships - CTI
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - AstraZeneca; Eisai; IgM Biosciences
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Pionyr (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
 
S. Lindsey Davis
Stock and Other Ownership Interests - Johnson & Johnson/MedTech
Speakers' Bureau - Allergan (I)
Research Funding - Boston Scientific (I); Bristol-Myers Squibb (Inst); EMD Serono (Inst); I-Mab (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Symphogen (Inst); TriSalus Life Sciences (Inst); Tvardi Therapeutics (Inst)
 
Adam Burgoyne
Consulting or Advisory Role - Clinical Care Options; Deciphera; Exelixis; Genentech/Roche; Kuur Therapeutics
Speakers' Bureau - AstraZeneca; Deciphera
 
David Tweardy
No Relationships to Disclose
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Elevar Therapeutics; Exelixis; Hepion Pharmaceuticals; Imvax; Lilly; Medivir; Merck; QED Therapeutics; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Codiak Biosciences (Inst); Debiopharm Group (Inst); Genoscience Pharma (Inst); Genoscience Pharma (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
Ahmed Omar Kaseb
Honoraria - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Research Funding - Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
 
Sofia de Achaval
Employment - Tvardi Therapeutics
Stock and Other Ownership Interests - Tvardi Therapeutics
Patents, Royalties, Other Intellectual Property - Patents with Tvardi Therapeutics, Inc.
 
Imran Alibhai
Employment - Tvardi Therapeutics
Leadership - Tvardi Therapeutics
Stock and Other Ownership Interests - Tvardi Therapeutics
Patents, Royalties, Other Intellectual Property - Tvardi Therapeutics
 
John S. Kauh
Employment - Glenmark; HUTCHMED; Lilly; Tvardi Therapeutics
Stock and Other Ownership Interests - HUTCHMED; Lilly; Tvardi Therapeutics
Travel, Accommodations, Expenses - Glenmark; HUTCHMED; Lilly; Tvardi Therapeutics